Entering the year 2020, Adimmune(4142) has had multiple reports of success, signing a 5 year production supply contract with French pharmaceutical company Sanofi-Aventis’s subsidiary Protein Sciences. Total revenue of December 2019 was also fruitful, coming in at around 274 million NTD, setting a new record for monthly revenue since the company’s inception, a 1522.36% increase compared to the same period last year. Cumulative revenue for 2019 totaled at 1.299 billion NTD last year, a sixty percent increase in contrast with 2018’s revenue of 822 million NTD.
Adimmune CEO Chan,Chi Shean personally led a team to Lyon, France, to visit long time partner, Sanofi-Aventis’s subsidiary Protein Sciences, to sign the production supply contract. Demonstrating that Sanofi-Aventis is an invaluable long term partner to Adimmune, as well as displaying Adimmune’s great leap forwards in the globalization of their products and supplies.
The newly signed production supply contract will be extending the coproduction of Flublok® Quadrivalent Influenza Vaccine. From the current contract ending in 2022 to 2027, Adimmune will continue to produce and supply Flublok, and will expand production and support for Flublok in other global markets.
Adimmune started collaborating on the production of Flublok with Protein Sciences in 2015, producing Flublok using a sterile injection production line in the Tanzi district as well as going through phase III human clinical vaccine trials in the United States, and started producing the vaccine commercially after receiving FDA approval in 2017.